CD38 and Miyoshi myopathy: To determine whether the increase in CD38 antigen density enables superior anti-MM activity of the anti-CD38 mAb daratumumab we pretreated MM cell lines with ricolinostat and initiated ADCC with daratumumab or control antibody.